Cazzaniga ME, Pinotti G, Montagna E, et al. - Researchers used a retrospective cohort of metastatic breast cancer (MBC) patients and reported the use of metronomic chemotherapy (mCHT) in the cohort, to gather data concerning the various types and regimens of drugs used, their efficacy as well as safety. They gathered the data of 584 metastatic breast cancer patients managed with mCHT from January 2011 to December 2016. During the observation period, a rise was reported in the use of VRL-based regimens (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones, whereas CAPE-based and MTX-based regimens continued to be stable. For VRL-based regimens in the 1st-line setting, the highest ORR and DCR were seen. They found the longest median PFS in VRL-combination regimens and in CAPE-single agent, supposing VRL-single agent as the referee therapy. Novel data originating from the real-life setting was offered by the VICTOR-6 study and new information was added on the use of mCHT as a choice of treatment for MBC patients.